Grenoble, a France-based microcarrier supplier for cell culture in the bioreactor, Carroucell raised EUR 1.5 million. The Series A funding took place on September 7, 2022. Novalis Biotech Acceleration fund led the financing for the company. Meanwhile, Crédit Agricole des Savoie (CADS) and Bpifrance joined in the investment.
As a part of the deal, Jan Van den Berghe, co-founder and managing director of Novalis Biotech, has also been appointed to the board of directors for Carroucell.
Purpose of financing for Carroucell
With the latest capital investment, the company intends to accelerate corporate growth through the industrialization of its platform technology.
It also seeks to ramp up the mass production processes to GMP standards.
What the Carroucell officials have to say
Takis Breyiannis, CEO of Carroucell, said, “The complex environment of cell culture in bioreactors and the increasing number of new applications requires an innovative approach to guarantee the balance of the system. Carroucell’s microcarrier plays the role of regulator of this system by ensuring its optimization.”
In addition, Tarek Fathallah, Founder and President of Carroucell, said, “For the first time, microcarrier customization and more customer-oriented service are available for the development of the new applications into the cell culture and bioproduction market. There are many challenges with biomanufacturing performance. We believe in our unique microcarrier technology and ability to address customer-specific needs. It will overcome most challenges and stimulate a revolution in the sector moving forward.”
What the investor has to say
Jan Van den Berghe, co-founder and managing director of Novalis Biotech, further added, “Carroucell is creating a new standard in biomanufacturing, which could help to facilitate patient access to many more innovations in cell and gene therapy in the future. When customers adopt Carroucell’s technology platform, they can optimize the yield and the quality of the cell culture, solving the low-performance problem in bioproduction we see today.”
About the company
Tarek Fathallah founded the firm in 2016. Carroucell aims to disrupt the biomanufacturing sector. It offers patented, innovative microcarrier and flexible process solutions for customers. Carroucell enjoyes partnership with Etablissement Français du Sang (EFS), which enabled the validation of its microcarriers and facilitated first commercial orders. It developed a disruptive technology platform that offers unique flat shape microcarriers with a xenofree glass composition for cell culture in bioreactors. Integrating the novel microcarriers with the flexibility of the production process allows for a faster, more optimized scale-up of the clinical phases.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
